冠心病辨证与血凝纤溶系统关系的临床研究

目的：探讨凝血纤溶系统的变化与冠心病（CHD）辨证的关系。方法：在对269例冠心病人临床辨证的基础上，检测分析CHD各证型病人及健康对照组的抗凝血酶Ⅲ（ATⅢ）、血小板仅颗粒膜蛋白（GPM-140）、纤溶酶原激活物抑制物（PAI-1）、组织型纤溶酶原激活物（t—PA）等血凝纤溶系统指标。结果：较之健康对照组，冠心病的各证型组的异常均有显著性意义（均P〈0．01）。各证型组之间比较，心血瘀阻证和痰阻心脉证的5项指标异常的程度最明显，尤以心血瘀阻证为著。结论：①抗凝血指标（AT11I）的变化与冠心病临床辨证具有一定的相关性。②GMP-140显著升高可作为冠心病监测和血栓前状态评价的有效指标。③冠心病各证型均存在纤溶活性（t—PA与PAI—1）低下状态，心血瘀阻和痰阻心脉证尤为显著。

Clinical Study the Relation CHD Syndrome Differentiation with Coagulation and Fibrinolysis System

Objective ： to probe relation syndrome differentiation. Methods： detection and magglutination fibrinolytic system indicators of the between coagulation and fibrinolysis system changes and CHD analysis AT Ⅲ, GPM - 140, PAI- 1, t - PA and so on he- CHD different syndrome type and control group. Results： Abnormality of CHD different syndrome type showed significant difference Comparison with control group （P 〈 0. 01 ）. Heart blood stasis syndrome and phlegm syndrome 5 indicators abnormality showed the most obvious, particular in heart blood stasis. Conclusion： ①change of antcoagulant indicators has relation with CHD clinical syndrome differentiation. ②Significantly increased GMP - 140 can take as the effective indicator in CHD monitoring and evaluation of the prethrombotic state. ③low fibrinolytic activity exist in the CHD different syndrome type, particular in heart blood stasis and phlegm syndrome.